Breaking News Bar

Business News and Information

Week in Review: China Green Lights NASDAQ-style Exchange for Young Companies

Government and Regulatory   China approved a new Shanghai stock exchange similar to NASDAQ that will be a venue for debut offerings from young high tech companies; Deals and Financings iKang Healthcare, a private China healthcare chain, completed a $1.4 billion privatization backed by an Alibaba investment arm and Yunfeng Capital; Circassia Pharma of Oxford signed a $32.7 million agreement to acquire US and China marketing rights for a respiratory failure product; Immunochina Pharma of Beijing closed a $20.4 million Series C financing to advance its CAR-T candidates; Trials and Approvals   Shanghai 's I-Mab Biopharma was cleared to start US Phase I trials of its novel CD73 antibody, an immunotherapy, in patients with advanced solid tumors' Industry Insight   German Merck CEO, Stefan Oschmann, expects China biopharma to continue its growth, with a China company becoming one of the top 50 global biopharmas. Stock Symbols: (NSDQ: KANG) (NYSE: BABA) (LSE: CIR) (Xetra: MRK) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear